EGFR and neoplasm: The data that continue to emerge from the ADAURA trial, for example,25 in which adjuvant therapy is applicable to even stage 1b disease, make clear the importance of seeking EGFR mutations as early as possible in either the resected tumour or, ideally, presurgical specimens if available, and targeted therapies are now becoming established in the neoadjuvant setting.